DATA - The Buzz Show: Cerevel Therapeutics (NASDAQ: CERE) Results for CVL-231 in Phase 1b Clinical Trial

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Cerevel Therapeutics Sees Positive Results for CVL-231 in Phase 1b Clinical Trial ”

Cerevel Therapeutics (NASDAQ: CERE) surged over 59% in premarket trading after the company announced positive results from its Phase 1b clinical trial of CVL-231.

CVL-231 was generally well-tolerated, and the Company plans to advance CVL-231 to Phase 2 development in schizophrenia and to evaluate the potential for this mechanism in other populations, including dementia-related psychosis.

Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling diseases with a targeted approach to neuroscience that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a range of neuroscience diseases, including Parkinson’s, epilepsy, schizophrenia, and substance use disorder.

For more information, please visit: Cerevel Therapeutics

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

The post “The Buzz” Show: Cerevel Therapeutics (NASDAQ: CERE) Results for CVL-231 in Phase 1b Clinical Trial first appeared on Financial Buzz .

For further details see: